Cancer Research Technology
Log in Register
Menu

Anti-CD22 [To15]

Invented by Dr Jacqueline Cordell from University of Oxford
Invented at University of Oxford

Info

Catalogue Number 151792
Applications FACS
Antigen/Gene or Protein Targets CD22
Reactivity Human
Relevance SIGLEC-2 is first expressed in the cytomplasm of pre- and pro- B cells. SIGLEC-2 is broadly expressed in normal and neoplastic B cells and absent from other leucocytes and tissues. SIGLEC-2 is a member of the immunoglobulin superfamily and serves as an adhesion receptor for sialic acid-bearing ligands expressed on erythrocytes and all leukocyte classes. It also associates with tyrosine kinases and play a role in signal transduction and B-cell activation. SIGLEC-2 is strongly expressed in hairy cell leukaemias.
Host Mouse
Immunogen Tonsil cells
Subclass IgG2b kappa
Myeloma Used P3/NS1/1-Ag4.1
Recommended Growing Conditions RPMI 1640 + 10% FCS + penicillin (100U/ml) + streptomycin (100mg/l) + glutamine (2mM) + HAT. Ultroser G (**) can be used at 1% if the cells are not growing well.Please note that this cell line has not been weaned out of HAT.
Research Area Adhesion, Cancer, Cell Signaling & Signal Transduction, Immunology, Stem Cell Biology

References

There are 2 reference entries for this reagent.

View All References

References: 2 entries

Mason et al. 1987. Blood. 69(3):836-40. PMID: 3101766.

Value of monoclonal anti-CD22 (p135) antibodies for the detection of normal and neoplastic B lymphoid cells.

Europe PMC ID: 3101766


Add a reference

References: 2 entries

Mason et al. 1987. Blood. 69(3):836-40. PMID: 3101766.

Value of monoclonal anti-CD22 (p135) antibodies for the detection of normal and neoplastic B lymphoid cells.


Add a reference